NZ604801A - Synthesis and use of focal adhesion kinase inhibitors - Google Patents

Synthesis and use of focal adhesion kinase inhibitors

Info

Publication number
NZ604801A
NZ604801A NZ60480111A NZ60480111A NZ604801A NZ 604801 A NZ604801 A NZ 604801A NZ 60480111 A NZ60480111 A NZ 60480111A NZ 60480111 A NZ60480111 A NZ 60480111A NZ 604801 A NZ604801 A NZ 604801A
Authority
NZ
New Zealand
Prior art keywords
focal adhesion
adhesion kinase
synthesis
kinase inhibitors
fak
Prior art date
Application number
NZ60480111A
Other languages
English (en)
Inventor
L Sun Connie
Carl Henry Behrens
Yixiong Lei
Hui-Yin Li
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of NZ604801A publication Critical patent/NZ604801A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ60480111A 2010-06-30 2011-06-28 Synthesis and use of focal adhesion kinase inhibitors NZ604801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ604801A true NZ604801A (en) 2015-03-27

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60480111A NZ604801A (en) 2010-06-30 2011-06-28 Synthesis and use of focal adhesion kinase inhibitors

Country Status (10)

Country Link
US (1) US9505719B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588476A4 (cg-RX-API-DMAC7.html)
JP (1) JP5923499B2 (cg-RX-API-DMAC7.html)
CN (1) CN103168037A (cg-RX-API-DMAC7.html)
AU (1) AU2011280031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2803005A1 (cg-RX-API-DMAC7.html)
MX (1) MX343894B (cg-RX-API-DMAC7.html)
NZ (1) NZ604801A (cg-RX-API-DMAC7.html)
WO (1) WO2012012139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300012B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
WO2026086879A1 (zh) * 2024-10-25 2026-04-30 应世生物科技(南京)有限公司 Fak抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
BRPI0715423A2 (pt) 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
EP2464642A4 (en) 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
JP5923499B2 (ja) 2016-05-24
ZA201300012B (en) 2013-09-25
MX2012014986A (es) 2013-07-03
MX343894B (es) 2016-11-28
US9505719B2 (en) 2016-11-29
CA2803005A1 (en) 2012-01-26
AU2011280031A1 (en) 2013-01-10
JP2013529687A (ja) 2013-07-22
US20140235635A1 (en) 2014-08-21
AU2011280031B2 (en) 2015-09-10
EP2588476A4 (en) 2014-07-23
CN103168037A (zh) 2013-06-19
EP2588476A1 (en) 2013-05-08
WO2012012139A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
MX348623B (es) Proceso y sistema de reaccion para la preparacion de metanol.
PH12014502775A1 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
MY166026A (en) Tetrahydro-pyrido-pyrimidine derivatives
WO2012087628A3 (en) Production of polycrystalline silicon by the thermal decomposition of dichlorosilane in a fluidized bed reactor
EG27128A (en) Process for the production of light olefins from synthesis gas
MX350643B (es) Procedimiento para la produccion de acetato de vinilo.
PH12012500825A1 (en) Methods of synthesis and purification of heteroaryl compounds
PH12013500343A1 (en) Production method of intermediate compound for synthesizing medicament
MX350003B (es) Procedimiento para la fabricación de derivados de dibenzoilmetano.
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
MX2012014986A (es) Sintesis y uso de inhibidores de cinasa.
IN2015DN00660A (cg-RX-API-DMAC7.html)
AU2012264468A1 (en) Catalytic process for the conversion of a synthesis gas to hydrocarbons
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
WO2014087208A3 (en) A process of preparing alcaftadine
GB201104203D0 (en) Chemical process
GB2489362B (en) Process for the conversion of synthesis gas
MX379124B (es) Métodos para producir molindona y sus sales.
TR201903717T4 (tr) Sentez gazından etanol üretiminde kontamine edici organizmalardan kaynaklanan istenmeyen yan ürünlerin oluşumunun kontrol edilmesine yönelik yöntem.
SA112330994B1 (ar) عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً
WO2012050623A3 (en) Novel phenoxyisobutyric acid compounds and methods for synthesis
WO2011104634A3 (pt) Produção de propilenoglicol a partir de glicerina
WO2011151442A3 (en) Process for producing aliskiren
SA113340412B1 (ar) عملية جديدة لتصنيع إيڤابرادين وأملاح إضافة منه مع حمض مقبول صيدلانياً
MX359424B (es) Proceso para la preparación de un precursor de estatina.

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR CONNIE, SUN ADDED

Effective date: 20130221

Free format text: INVENTOR LI, HUI-YIN REMOVED

Effective date: 20130221

ASS Change of ownership

Owner name: VERASTEM, INC, US

Effective date: 20140313

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20150818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180918

LAPS Patent lapsed